Compare · BSEM vs MRNA
BSEM vs MRNA
Side-by-side comparison of BioStem Technologies Inc. (BSEM) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSEM and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $87.10B, about 4730.9x BSEM ($18.4M).
- MRNA has been more active in the news (15 items in the past 4 weeks vs 9 for BSEM).
- MRNA has more recent analyst coverage (25 ratings vs 0 for BSEM).
- Company
- BioStem Technologies Inc.
- Moderna Inc.
- Price
- -
- -
- Market cap
- $18.4M
- $87.10B
- 1M return
- -
- -1.01%
- 1Y return
- -
- +769.75%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 9
- 15
- Recent ratings
- 0
- 25
BioStem Technologies Inc.
BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain, CryoTek and SteriTek processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest BSEM
- Chief Financial Officer Poe Brandon converted options into 2,699 shares, increasing direct ownership by 5% to 60,763 units (SEC Form 4)
- SEC Form 10-Q filed by BioStem Technologies Inc.
- BioStem Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BioStem Technologies Reports Third Quarter 2026 Financial Results; Grows Hospital Revenue for Second Consecutive Quarter as Customers Expand Use of Portfolio
- Chief Accounting Officer Fortunato Michael A converted options into 970 shares, increasing direct ownership by 1% to 69,634 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by BioStem Technologies Inc.
- SEC Form SCHEDULE 13G filed by BioStem Technologies Inc.
- SEC Form SCHEDULE 13G filed by BioStem Technologies Inc.
- Chief Commercial Officer Hassett Barry converted options into 253 shares, increasing direct ownership by 5% to 5,256 units (SEC Form 4)
Latest MRNA
- Moderna Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Moderna Outlines Next Phase of Growth at Analyst Day
- Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older
- Moderna to Present at Upcoming Conference in November 2026
- Chief Operating Officer Andres Juan was granted 7,898 stock options and was granted 16,955 restricted stock units (SEC Form 4)
- SEC Form 10-Q filed by Moderna Inc.
- Moderna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates
- Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines